Medicus Pharma Ltd. (MDCX) News
Track canonical SquawkNews coverage tagged to MDCX, Medicus Pharma Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Medicus Pharma Ltd. (MDCX) Seeks FDA OK for Seamless Teverelix Phase 2b/3 To Enable Partnering
Medicus Pharma submitted an optimized seamless Phase 2b/3 protocol to the FDA for Teverelix in advanced prostate cancer, aiming to cut planned enrollment to ~600 from ~1,500 and enable partnering, subject to FDA feedback
REGULATION | Sep 29, 2026, 11:33 AM UTC
L
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategyPHILADELPHIA, Sept. 29,
REGULATION | Sep 29, 2026, 11:33 AM UTC
H
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
Medicus Pharma Ltd. (NASDAQ: MDCX ) on Monday announced it will concentrate all future internally sponsored clinical development for its SkinJect asset exclusively on Gorlin syndrome patients presenting with multiple bas
LIVE | Sep 21, 2026, 11:32 AM UTC
L
MDCX - Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
MDCX - Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
NEWS | Sep 21, 2026, 11:30 AM UTC
L
Dr. Raza Bokhari Discloses Investment at Medicus Pharma Ltd. with 5.3% Stake
Dr. Raza Bokhari, Chief Executive Officer and Executive Chairman of Medicus Pharma Ltd., disclosed a 5.3% stake in the company’s common shares. He filed a Schedule 13D on Sep. 14, 2026, detailing direct holdings, stock o
EQUITY | Sep 14, 2026, 09:00 PM UTC
L
MDCX - Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the L
MDCX - Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
EQUITY | Sep 10, 2026, 11:30 AM UTC
L
MDCX - Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
MDCX - Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
EQUITY | Sep 08, 2026, 11:30 AM UTC
M
Medicus Pharma inks Pfizer CD228V co-development and global license deal
Medicus Pharma entered a co-development and license agreement with Pfizer for CD228V, a worldwide, early clinical-stage CD228-targeting antibody-drug conjugate. The deal grants an exclusive, sublicensable patent license
EQUITY | Sep 03, 2026, 12:04 PM UTC
L
Medicus Pharma reports Q2 2026 results and corporate update
Medicus Pharma (MDCX) reports its second quarter 2026 financial results and provides a corporate update, with no additional figures included in the provided alert.
EARNINGS | Aug 12, 2026, 10:00 PM UTC
M
MDCX Appoints CEO of Antev Limited
MDCX appoints Dr. Faisal Mehmud as CEO
EQUITY | Aug 03, 2026, 11:30 AM UTC
H
UAE Grants Authorization
UAE authorizes phase 2a study
EQUITY | Jul 31, 2026, 11:30 AM UTC
H
MDCX Receives UAE Health Authorization
MDCX gets UAE approval for medicine study
EQUITY | Jul 31, 2026, 11:30 AM UTC
L
Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study
Medicus Pharma announced...
REGULATION | Jul 27, 2026, 01:10 PM UTC
L
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ: CRIS ) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ: HUMA ) shares moved upwards by 5.45% to $0.71. The marke
EQUITY | Jul 01, 2026, 09:05 PM UTC